

# OBJ LIMITED

ABN 72 056 482 636

Level 1, 33 Ord Street  
West Perth WA 6005,  
PO Box 637 West Perth WA 6872  
Telephone: +61 8 9420 9300  
Facsimile: +61 8 9481 2690

*Thursday 2 December 2004*

Company Announcements Office  
Australian Stock Exchange Limited

*By e-Lodgement*

## ***Ex-Bayer Scientist joins OBJ***

OBJ Limited (OBJ) is pleased to announce today that Dr Maud Eijkenboom has joined OBJ as Scientific Liaison Officer. Dr Eijkenboom will assist the company in preparing its clinical and validation program to ensure compatibility with the requirements of major US and European Pharmaceutical companies.

Dr Eijkenboom, who until recently was one of Bayer Healthcare's senior drug development scientists, has significant experience in drug development and evaluation programs. Dr Eijkenboom has worked with a number of major USA and European Pharmaceutical companies including Millennium, Janssen (J&J) and Novartis.

Dr Eijkenboom will develop OBJ's validation programs to demonstrate the ability of the Dermaportation through-the-skin drug delivery technology to mobilise a range of proprietary third-party drugs currently suffering from poor permeability or excessive side effects.

Dr Eijkenboom will work with OBJ's expert medical group in determining which generic drugs can be administered more effectively and efficiently using the company's Dermaportation technology.

OBJ recently announced a clinical trial and drug delivery study with the Western Australian Biomedical Research Institute (WABRI). However, Dr Eijkenboom hopes to expand this development program to incorporate a number of major international scientific testing centres in Europe and USA by mid 2005.

For more information:

**David Steinepreis**  
9420 9300  
0411 510 781

**Jeffrey Edwards**  
9344 33011  
041 791 2211